Page last updated: 2024-12-11
ll d42067 alpha
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
simaomicin alpha: from an actinomycete strain; RN given refers to (7alpha,11beta,14alpha)-(+)-isomer; RN for cpd without isomeric designation not avail 11/90; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5487067 |
| MeSH ID | M0181561 |
Synonyms (9)
| Synonym |
|---|
| simaomicin alpha |
| 100157-22-0 |
| ll d42067alpha |
| ll-d42067alpha |
| 2h-xantheno(2',3':6,7)(1,3)benzodioxino(4,5-fg)isoquinoline-1,15-dione, 7a,8,11,12,13,14-hedahydro-11,14,16,17-tetrahydroxy-9-methoxy-2,3-dimethyl-, (7aalpha,11beta,14alpha)-(+)- |
| 3,7,10,28-tetrahydroxy-14-methoxy-24,25-dimethyl-12,18,20-trioxa-25-azaheptacyclo[15.11.1.02,15.04,13.06,11.021,29.022,27]nonacosa-1(28),2(15),3,6(11),13,21(29),22(27),23-octaene-5,26-dione |
| DTXSID30905231 |
| 11,14,16,17-tetrahydroxy-9-methoxy-2,3-dimethyl-7a,8,11,12,13,14-hexahydro-2h,6h-xantheno[2',3':6,7][1,3]benzodioxino[4,5-fg]isoquinoline-1,15-dione |
| simaomicin |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.84
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||